These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 31476958

  • 1. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
    Mundisugih J, Fernando H, Bergin P, Hare J, Kaye D, Leet A, McGiffin D, Taylor AJ.
    Prog Transplant; 2019 Dec; 29(4):327-334. PubMed ID: 31476958
    [Abstract] [Full Text] [Related]

  • 2. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 3. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 4. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C.
    Lancet; 2016 Dec 17; 388(10063):3006-3016. PubMed ID: 27871759
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM, Keating GM.
    Drugs; 2003 Dec 17; 63(24):2803-35. PubMed ID: 14664658
    [Abstract] [Full Text] [Related]

  • 7. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, Guillemain R, Lelong B, Pol A, Treilhaud M, Vermes E, Dorent R, Lemay D, Blanc AS, Boissonnat P.
    J Heart Lung Transplant; 2007 Jul 17; 26(7):693-9. PubMed ID: 17613399
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.
    Hashim M, Alsebaey A, Ragab A, Soliman HE, Waked I.
    Ann Hepatol; 2020 Jul 17; 19(5):541-545. PubMed ID: 32768592
    [Abstract] [Full Text] [Related]

  • 9. Belatacept for kidney transplant recipients.
    Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.
    Cochrane Database Syst Rev; 2014 Nov 24; 2014(11):CD010699. PubMed ID: 25416857
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 24; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 14. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct 24; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 15. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S, Paritala P, Rao Ch UM, Athmakuri SM, Reddy VS, Sahariah S.
    Saudi J Kidney Dis Transpl; 2014 Jan 24; 25(1):9-15. PubMed ID: 24434376
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group.
    N Engl J Med; 2006 Nov 09; 355(19):1967-77. PubMed ID: 17093248
    [Abstract] [Full Text] [Related]

  • 18. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD.
    Chin Med J (Engl); 2012 Mar 09; 125(6):1135-40. PubMed ID: 22613543
    [Abstract] [Full Text] [Related]

  • 19. Antithymocyte globulin induction therapy adjusted for immunologic risk after heart transplantation.
    Czer LS, Phan A, Ruzza A, Rafiei M, Setareh-Shenas S, Caceres M, Awad M, Soliman C, Mirocha J, De Robertis M, Kass RM, Trento A.
    Transplant Proc; 2013 Mar 09; 45(6):2393-8. PubMed ID: 23953554
    [Abstract] [Full Text] [Related]

  • 20. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM, Jang HR, Kwon CH, Huh WS, Kim GS, Kim SJ, Joh JW, Oh HY.
    Transplant Proc; 2012 Jan 09; 44(1):167-70. PubMed ID: 22310606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.